Phase I Arm A clinical trials

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

This study is testing a new drug, GDC-7035, for people with advanced solid tumours that have a specific genetic change called KRAS G12D. Researchers want to see if it's safe, how it works in the body, and if it helps shrink tumours, both on its own and with other treatments.